regenerative medicine research

AION Healthspan is a clinical-stage biotechnology company whose mission is to extend human healthspan by developing cellular therapies that prevent, delay, and reverse age-related diseases. Founded on four decades of research at the University of Miami's Diabetes Research Institute and Cell Transplant Center, it is developing its REJUVXL™ cell therapy platform, with a Phase 1/2a clinical trial in Chronic Kidney Disease that commenced in Q1 2025, and plans to expand to indications including acute lung conditions and diabetes.

cell therapy developmentclinical trials

Britecyte is a regenerative medicine company based in Frederick, MD, founded in 2020. It develops Biorestoration therapies using a proprietary adipose tissue technology platform that preserves native adipose architecture while removing immunogenic components, enabling allogeneic transplantation. Its commercial products include Liposana for foot fat pad loss and Lipoderma for aesthetic soft tissue restoration.

adipose tissue processing technologyallogeneic transplantationclinical trials

ChemRegen is a regenerative medicine research and development company located in San Diego, California, combining stem cell biology and drug development. Its initial technology is based on work done in collaboration between Dr. Mark Mercola of the Sanford Burnham Research Institute and Dr. John Cashman of the Human BioMolecular Research Institute, who also serves as Chief Operating Officer of ChemRegen. ChemRegen provides design, implementation, and interpretation of pre-clinical regenerative medicine drug development.

drug developmentpre-clinical drug developmentstem cell biology

Eluciderm is a clinical-stage regenerative medicine small-molecule pharmaceutical company based in San Diego, CA. It has developed a platform of small molecules that selectively modulate multiple Poly(ADP-ribose) polymerase (PARP) enzymes to guide tissue repair away from fibrosis and toward organized tissue regeneration. Its lead candidate ELU42 is a topical spray-on therapy in a Phase I/IIA clinical trial for diabetic foot ulcers.

clinical stage drug developmentsmall-molecule PARP modulation platformtopical spray-on drug formulation